Login / Signup

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomised study in rheumatoid arthritis.

Daniel E FurstJanusz JaworskiRafal WojciechowskiPiotr WilandAnna DudekMarek KrogulecSlawomir JekaAgnieszka ZielinskaJakub TreflerKatarzyna Bartnicka-MaslowskaMagdalena Krajewska-WlodarczykPiotr A KlimiukSang Joon LeeSung Hyun KimYun Ju BaeGo Eun YangJae Kyoung YooJonathan KayEdward C Keystone
Published in: Rheumatology (Oxford, England) (2021)
Efficacy, pharmacokinetics, safety and immunogenicity of CT-P17 and reference adalimumab were comparable after 1 year of treatment, including after switching from reference adalimumab to CT-P17.
Keyphrases